Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell Therapeutics
Pharma
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
The two companies attributed the termination to enrollment challenges as the multiple myeloma treatment landscape shifts to more powerful treatments.
Angus Liu
Sep 25, 2024 10:52am
Gilead's Kite exits China cell therapy JV with Fosun Pharma
Sep 19, 2024 4:23pm
FDA signs off on first engineered cell therapy for a solid tumor
Aug 2, 2024 8:56am
Bristol Myers’ top challenges, as seen by analysts
Jul 12, 2024 12:00pm
J&J, Legend's Carvykti extends lives in multiple myeloma trial
Jul 2, 2024 9:58am
ASCO: BMS' triplet, Iovance's Amtagvi-Keytruda target melanoma
May 23, 2024 5:00pm
